Jul 21, 2026 07:00AM
Jul 21, 2026 07:00AM
May 7, 2026 04:15PM
Apr 20, 2026 10:21AM
Apr 20, 2026 07:43AM
Apr 20, 2026 07:30AM
Mar 28, 2026 12:36PM Nektar presents rezpegaldesleukin data at dermatology meeting
Mar 28, 2026 12:36PM
Mar 20, 2026 10:00AM
Mar 20, 2026 10:00AM
Mar 10, 2026 09:08AM
Feb 19, 2026 05:31PM
Feb 17, 2026 07:00AM
Feb 16, 2026 05:31PM Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
Feb 10, 2026 07:01AM
Feb 10, 2026 07:00AM
Dec 16, 2025 07:30AM
Dec 16, 2025 07:30AM
Nov 8, 2025 05:45PM
Nov 6, 2025 04:15PM
Oct 22, 2025 08:00AM Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
Sep 18, 2025 08:46AM
Sep 18, 2025 08:45AM
Sep 9, 2025 07:00AM
Aug 7, 2025 04:15PM
Jul 29, 2025 09:01AM
Jul 29, 2025 09:00AM
Jun 24, 2025 07:31AM Nektar Therapeutics (NKTR): REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe AD
Jun 24, 2025 07:30AM
May 8, 2025 04:15PM
Mar 12, 2025 04:15PM
Feb 26, 2025 07:01AM
Feb 26, 2025 07:00AM
Feb 24, 2025 07:00AM
Feb 24, 2025 07:00AM Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th
Feb 24, 2025 07:00AM
Feb 10, 2025 07:01AM
Feb 10, 2025 07:00AM
Dec 7, 2024 12:00PM
Nov 4, 2024 08:30AM
Nov 4, 2024 08:30AM
Mar 19, 2024 04:15PM DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
Jan 22, 2024 08:23AM
Dec 12, 2022 10:05AM
Apr 29, 2022 06:59AM
Apr 14, 2022 04:33PM
Apr 14, 2022 04:30PM
Mar 15, 2022 06:37AM
Mar 14, 2022 07:00AM Bristol-Myers Squibb (BMY), Nektar (NKTR) Announce Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo Did Not Meet Primary Endpoint
Mar 14, 2022 06:59AM

326,531 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All